Keizo Horibe

TL;DR: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.

TL;DR: The results suggest that TP53 and RAS-pathway mutations predicted a dismal prognosis, when associated with CK and MDS/MPNs, respectively, however, for patients with mutated TP53 or CK alone, long-term survival could be obtained with transplantation.

TL;DR: Pediatric ALL with induction failure is highly heterogeneous, and patients who have T-cell leukemia appear to have a better outcome with allogeneic stem-cell transplantation than with chemotherapy, whereas patients who has precursor B- cell leukemia without other adverse features appear toHave a better outcomes with chemotherapy.

TL;DR: A high survival rate, 75.6% at 5 years, was achieved for childhood with de novo AML in the AML99 trial, and the treatment strategy was well tolerated with only 1.7% induction death rate and 3.5% remission death rate.

TL;DR: Clinical outcome of children and adolescents with Ph-positive ALL has improved with advances in transplantation and chemotherapy, and transplantations with matched related donors and unrelated donors were equivalent and offered better disease control compared with chemotherapy alone.